• 1. Stereogenic metal centres – from Werner to supramolecular chemistry
  Edwin C. Constable Chem. Soc. Rev. 2013 42 1637
• 2. LIX.—Electro-osmotic experiments on the reversal of the electrical charge of colloids and precipitates and the preparation of stable sols with a charge opposite in sign to that commonly obtained
  Jnanendra Nath Mukherjee,Bankim Chandra Roy J. Chem. Soc. Trans. 1924 125 476
• 3. Quinoline, quinazoline and acridone alkaloids
  Joseph P. Michael Nat. Prod. Rep. 2007 24 223
• 4. The physical identity of enantiomers
  Alan Newton Campbell,Frederick Campbell Garrow Trans. Faraday Soc. 1930 26 560
• 5. 696. The formula of sodium paratungstate
  K. Saddington,R. W. Cahn J. Chem. Soc. 1950 3526

• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Cinchona alkaloids Cinchona alkaloids
• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Cinchona alkaloids

Cinchonidine Dihydrochloride (CAS No. 24302-67-8): A Comprehensive Overview in Modern Pharmaceutical Research

Cinchonidine Dihydrochloride, identified by the Chemical Abstracts Service Number (CAS No.) 24302-67-8, is a compound of significant interest in the field of pharmaceutical chemistry and medicinal biology. Derived from the cinchona tree, this alkaloid derivative has garnered attention for its diverse pharmacological properties and potential therapeutic applications. This article provides an in-depth exploration of Cinchonidine Dihydrochloride, emphasizing its chemical structure, pharmacological mechanisms, recent research findings, and future prospects in drug development.

The molecular structure of Cinchonidine Dihydrochloride consists of a quinoline backbone with two hydroxyl groups and a diethylamino side chain. This unique configuration contributes to its remarkable biological activity, particularly in modulating ion channels and neurotransmitter systems. The compound exists as a dihydrochloride salt, which enhances its solubility and bioavailability, making it more suitable for pharmaceutical formulations.

In recent years, Cinchonidine Dihydrochloride has been extensively studied for its potential role in treating neurological disorders. Research has demonstrated its ability to interact with voltage-gated potassium channels, leading to changes in neuronal excitability. This property makes it a promising candidate for managing conditions such as epilepsy and neuropathic pain. Furthermore, studies have indicated that Cinchonidine Dihydrochloride may exhibit neuroprotective effects by reducing oxidative stress and inflammation in brain tissues.

One of the most compelling aspects of Cinchonidine Dihydrochloride is its interaction with the dopamine system. Preclinical studies have shown that it can modulate dopamine release and receptor activity, which may have implications for treating dopamine-related disorders such as Parkinson's disease. The compound's ability to enhance dopaminergic signaling without causing excessive side effects has made it an area of active investigation.

Recent advances in pharmacogenomics have also highlighted the potential of Cinchonidine Dihydrochloride in personalized medicine. By understanding genetic variations that influence drug metabolism and response, researchers can tailor therapeutic strategies to individual patients. This approach could improve the efficacy and safety of treatments involving Cinchonidine Dihydrochloride, particularly in patients with specific genetic profiles.

The synthesis and characterization of Cinchonidine Dihydrochloride have been refined through modern chemical techniques. High-performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR) spectroscopy are commonly employed to ensure high purity and structural integrity. These methods are crucial for developing reliable pharmaceutical formulations and conducting rigorous clinical trials.

The clinical development of Cinchonidine Dihydrochloride is progressing steadily, with several Phase II trials underway. These trials aim to evaluate its efficacy and safety in various neurological conditions. The results thus far have been encouraging, suggesting that Cinchonidine Dihydrochloride could become a valuable addition to the armamentarium of neurological therapies.

The future directions for research on Cinchonidine Dihydrochloride include exploring its potential in combination therapies and investigating long-term effects. By combining it with other pharmacological agents, researchers hope to achieve synergistic benefits that could enhance treatment outcomes. Additionally, understanding the long-term impact on patients will be crucial for ensuring its safe and effective use in clinical practice.

In conclusion, Cinchonidine Dihydrochloride (CAS No. 24302-67-8) represents a significant advancement in pharmaceutical research. Its unique chemical properties, coupled with promising preclinical findings, position it as a potent candidate for treating various neurological disorders. As research continues to uncover new applications and refine therapeutic strategies, the role of Cinchonidine Dihydrochloride in modern medicine is likely to expand significantly.

• 485-64-3(Cinchamidine)
• 70877-75-7(O-Desmethyl Quinidine)
• 118-10-5(Cinchonine)
• 485-71-2(Cinchonidine)
• 524-63-0(4-[(R)-hydroxy-[(1S,2S,4S,5R)-5-vinylquinuclidin-2-yl]methyl]quinolin-6-ol)
• 485-65-4(Hydrocinchonin)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)